Here is the Boston area, there is nothing boring about going to a museum on a Friday night. Tonight, Harvard’s Museum of Natural History host a multimedia, arts-meets science event called Bizarre Animals 2.0: An Evening of Contemporary Art Interventions."

Not to be outdone by the songs of science slated for the upcoming city science festival, tonight even include perfomances by The Hind Legs and Duck That.

On the evening of April 8, the Harvard Museum of Natural History will present a special evening of performance, multimedia, and art installations throughout its historic galleries. For two and half hours, 15 artists from across the country will transform the museum into laboratory, library, exploratorium, and stage. Through thoughtful interventions and captivating experiments, viewers will experience new ways to engage with the museum’s spaces, its collections, and its history.

The events are curated by Lisa Haber-Thomson (Harvard College ’02, Harvard GSD, ’10) and Tom Scanlon, from the Harvard Museum of Natural History.

British officials are one step closer to recommending the off-label use of the cancer drug Avastin to treat wet macular degeneration (wet MD), the most common cause of blindness, reports The Guardian.

The National Institute for Health and Clinical Excellence (NICE), the regulatory board which determines which drugs doctors can prescribe patients covered by UK’s National Health Service, will consider whether or not to approve the use of Avastin for the disease provided the safety and efficacy of the drug can be evaluated.

This decision comes at the heels of a recent study, published in the journal Eye, in which Avastin was found to be just as effective as the much more expensive drug Lucentis, which is currently approved to treat wet MD.

Genentech, which manufactures Lucentis and Avastin, however, continues to fight against its off-label use, refusing to assist in the necessary safety studies needed to give Avastin the green light.

To find out more about the controversy behind Avastin and its growing use to treat wet MD, read our story on treatment options for a related eye disease.